Revisiting the secretome analysis, CCL2, a chemokine implicated in cervical cancer, prostate cancer, and PDAC PNI [26–28], was identified as a potential player in guiding PDAC cells towards SCs; therefore, CCL2 was inhibited in CM via neutralizing antibody. Here, CCL2 is linked to prostate cancer.